Abstract

HCV is an important global health and economic problem through direct and indirect medical cost associated with managing liver disease, decreased work productivity. A hundred eighty million people are infected in the world. HCV is associated with the increasing liver related and all causes of mortality. Both HCV and Chronic Kidney Disease (CKD) have a negative impact on both morbidity and mortality.

The aim of this article is to reveal the close relationship between HCV and CKD, and to review the studies related with treatment of patients with HCV and different stages of CKD. Clinical use of Direct Antiviral Agents (DAAs) for the treatment in patients with HCV infection revolutionized the increase of sustained virological response (SVR), decreasing the duration of treatment and severe adverse events. Treatment of HCV infection in chronic renal impairment is reviewed in this article.

In conclusion, the treatment with DAAs is effective more than 90% and safe in patients with HCV infection and CKD. According to the stage of CKD, HCV infection should be treated.